Business

GSK Acquires Chinese Drug

Updated 2026-09-15 13:40 UTC 1 source Neutral

GlaxoSmithKline (GSK) has acquired global rights to a multiple myeloma treatment developed in China, expanding its pipeline and potentially boosting its market presence.

Coverage timeline — 1 article

STAT News

STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China

2026-09-15 13:29 UTC